Amphastar Pharmaceuticals, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $236.7M | $716.2M | $172.6M |
| Jun 2022 | $224.4M | $723.7M | $166.2M |
| Sep 2022 | $221.5M | $726.7M | $157.2M |
| Dec 2022 | $213.3M | $742.0M | $156.1M |
| Mar 2023 | $225.1M | $773.7M | $176.6M |
| Jun 2023 | $789.0M | $1.38B | $148.6M |
| Sep 2023 | $949.5M | $1.54B | $266.8M |
| Dec 2023 | $873.5M | $1.51B | $144.3M |
| Mar 2024 | $902.0M | $1.57B | $201.1M |
| Jun 2024 | $778.2M | $1.49B | $189.6M |
| Sep 2024 | $817.5M | $1.55B | $192.1M |
| Dec 2024 | $845.2M | $1.58B | $151.6M |
| Mar 2025 | $875.0M | $1.63B | $182.8M |
| Jun 2025 | $857.9M | $1.62B | $187.7M |
| Sep 2025 | $889.5M | $1.67B | $216.3M |
| Dec 2025 | $840.5M | $1.63B | $170.2M |
| Mar 2026 | $874.8M | $1.65B | $170.9M |
| Jun 2026 | $975.6M | $1.74B | $223.6M |